数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Assessment of short-term within-subject variability and test-retest reliability of Alzheimer's disease (AD)-related plasma biomarkers is important for real-world clinical implementation and interpretation in research studies.
方法
Participants from research studies at the Demen- tia Research Centre, University College London (UCL), which recruit individuals with and without cognitive impairment, were included if they had at least 2 serial blood sample collections, as part of their study enrol- ment, taken a maximum of 3 months apart.；Alzheimer's Research & Therapy (2026) 18:238 Sample collection and processing Serial blood sampling was performed on 92 participants either on the same day or within 92 days (~3 months).；Participants were not asked to fast prior to sample col- lection.
核心结论
Each point represents an individual biomarker effect estimate (beta) and error bars represent the corresponding 95% confidence intervals (CIs).；Adjusted p-values are NS unless other indicated; *p<0.05, p<0.01, *p<0.001 Page 9 of 12 Beament et al.；Cullen et al. reported test-retest variability of 20.0% for p-tau217, here we report a CVw of 11.2% [33]. ‖ 结论：In conclusion, core AD biomarkers show strong correla- tions and high test-retest reliability, with low within-sub- ject variability across assay platforms.
局限
Although we limited inclusion to samples collected within three months, during which substantial neuro- degenerative changes are unlikely to occur, we observed increased variability over longer sampling intervals for some biomarkers, which may reflect underlying physi- ological changes and warrants further investigation.
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。最大样本量约 92；设计 Meta 分析、系统综述。
全文来源
BMC OA PDF（正文 60,916 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Short-interval variability and test-retest reliability of Alzheimer's disease plasma biomarkers in a clinically heterogenous cohort.
- 期刊与标识：Alzheimers Res Ther · PMID 42947225 · DOI 10.1186/s13195-026-02180-8**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。